NOVYE VOZMOZhNOSTI TERAPII BOL'NYKh METASTATIChESKIM RAKOM MOLOChNOY ZhELEZY, POLUChAVShIKh RANEE ANTRATsIKLINI TAKSAN-SODERZhAShchUYu KhIMIOTERAPIYu: OBZOR LITERATURY I KLINIChESKIY SLUChAY
- Authors: Zhukova L.G1
-
Affiliations:
- Issue: No 8 (2013)
- Pages: 43-49
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281145
- ID: 281145
Cite item
Open Access
Access granted
Abstract
For a long time, anthracyclines and taxanes have occupied a prominent place in the treatment of metastatic breast cancer. However, at a certain stage of the disease the possibility of using these drugs are exhausted. Currently, we have the arsenal of other cytostatic agents having particular efficacy in the third and subsequent lines of therapy. However, until 2010 none of the drugs (or regimens) had proved efficacy in patients previously treated with anthracyclines and taxanes. Eribulin, a drug with a novel mechanism of action, demonstrating effectiveness and acceptable controlled toxicity, is really effective in third line of therapy for metastatic breast cancer.
Full Text
References
- Blum J., Jones S., Buzdar A. Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification. Eur J Cancer 2001;37(suppl 6):S190a.
- Blum J.L., Dieras V., Lo Russo P.M., et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-68.
- Reichardt R., et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-33.
- Fumoleau P., Largillier R., Trillet-Lenoir V., et al. Phase II study of capecitabine (Xeloda®) in pts with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes. Breast Cancer Res Treat 2001;69:285a.
- Vahdat L.T., Puitt B., Fabian C.J., et al. Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J Clin Oncol 2009;27:2954-61.
- Cortes J., Vahdat L.T., Blum J., et al. Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 2010;28:3922-28.
- Cortes J., O'Shaughnessy J., Loesch D., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
- Donoghue M., Lemery S., Yuan W. Eribulin Mesylate for the Treatment of Patients with Refractory Metastatic Breast Cancer: Use of a "Physician's Choice" Control Arm in a Randomized Approval Trial. Clin Cancer Res 2012;18:1496-505.
- Vahdat L.T., et al. Study 206: Phase II, Multicentre, Single-Arm Study of Eribulin as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast Cancer. SABCS 2012, poster P1-12-02.
- Vahdat L.T., et al. Study 208: Eribulin + Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer. SABCS 2012, poster P5-20-05.
- Blum J.L., et al. ABI-007 nanoparticle paclitaxel: Demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer. Proc ASCO 2003;abstract 64.
- Modi S., Currie V.E., Seidman A.D., et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracy-cline and taxane. Clin Breast Cancer 2005;6:55-60.
- Rha S.Y., Moon Y.H., Jeung H.C., et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;90(3):215-21.
- Ibrahim N.K., Rahman Z., Valero V., et al. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 1999;86(7):1251-57.
- Udom D.I., Vigushin D.M., Linardou H., et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36(2):177-82.
- Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21(3):
Supplementary files
